Skip to news
JQJO
Latest

Rybelsus Pill Shows Significant Cardiovascular Benefits | JQJO

Rybelsus Pill Shows Significant Cardiovascular Benefits

Rybelsus Pill Shows Significant Cardiovascular Benefits

Tap title to read story

0:00 / 0:42

Novo Nordisk announced that its oral diabetes drug, Rybelsus, demonstrated significant cardiovascular benefits in a late-stage trial. The four-year study showed a 14% reduction in cardiovascular death, heart attack, and stroke risk compared to a placebo in patients with diabetes and heart disease. This finding could expand Rybelsus's approval to include cardiovascular risk reduction, offering a convenient alternative to injectable treatments like Ozempic and Wegovy, which share the same active ingredient, semaglutide. The most common side effects were gastrointestinal issues, similar to injectable semaglutide. The company has already submitted applications for expanded approval in the US and EU.

Published · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.

Editorial policy and corrections · Our team

Bessent Urges Nvidia Outside CEO

Tap title to read story

0:00 / 0:00

Evans Responds to Seyfried’s Holmes

Tap title to read story

0:00 / 0:38

Rihanna Clarifies EJ Johnson Feud

Tap title to read story

0:00 / 0:31

Vikings Host Packers in Week 10

Tap title to read story

0:00 / 0:32

JQJO

Find your next story

Search JQJO’s current coverage.